Patents by Inventor Sylvain Cardinaud
Sylvain Cardinaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131138Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.Type: ApplicationFiled: December 22, 2021Publication date: April 25, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
-
Publication number: 20240124532Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.Type: ApplicationFiled: January 28, 2022Publication date: April 18, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research InstituteInventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
-
Publication number: 20230212231Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.Type: ApplicationFiled: May 26, 2021Publication date: July 6, 2023Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Baylor Research Institute, Assistance Publique - Hopitaux de Paris (APHP), Universite Paris Est Creteil Val de MarneInventors: Yves LEVY, Gérard ZURAWSKI, Sandra ZURAWSKI, Christine LACABARATZ, Sylvain CARDINAUD, Mathieu SURENAUD
-
Patent number: 10767167Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: GrantFiled: April 6, 2017Date of Patent: September 8, 2020Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
-
Publication number: 20170298328Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: ApplicationFiled: April 6, 2017Publication date: October 19, 2017Inventors: Pierre LANGLADE-DEMOYEN, Fransisco GARCIA PONS, Olivier ADOTEVI, Sylvain CARDINAUD, Christine NEUVEUT
-
Patent number: 9624479Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: GrantFiled: August 26, 2013Date of Patent: April 18, 2017Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
-
Patent number: 8858931Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: GrantFiled: July 31, 2006Date of Patent: October 14, 2014Assignees: Institut Pasteur, INSERMInventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
-
Publication number: 20140056932Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: ApplicationFiled: August 26, 2013Publication date: February 27, 2014Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEURInventors: Pierre LANGLADE-DEMOYEN, Fransisco GARCIA PONS, Olivier ADOTEVI, Sylvain CARDINAUD, Christine NEUVEUT
-
Patent number: 8003773Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: GrantFiled: July 12, 2007Date of Patent: August 23, 2011Assignees: Institut Pasteur, INSERMInventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
-
Publication number: 20100172878Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.Type: ApplicationFiled: July 31, 2006Publication date: July 8, 2010Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
-
Patent number: 7431928Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: GrantFiled: January 26, 2006Date of Patent: October 7, 2008Assignees: Institut Pasteur, Institut National de la Sante et de la RechercheInventors: Sylvain Cardinaud, André Habel, Pierre Langlade-Demoyen, François Lemonnier
-
Publication number: 20060115488Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: ApplicationFiled: January 26, 2006Publication date: June 1, 2006Inventors: Sylvain Cardinaud, Andre Habel, Pierre Langlade-Demoyen, Francois Lemonnier
-
Patent number: 7022325Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: GrantFiled: September 27, 2002Date of Patent: April 4, 2006Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche MedicaleInventors: Sylvain Cardinaud, André Habel, Pierre Langlade-Demoyen, François Lemonnier
-
Publication number: 20050163796Abstract: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications. Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs: 1 to 18 and functional derivatives thereof. The invention also relates to antibodies directed against said peptides.Type: ApplicationFiled: September 27, 2002Publication date: July 28, 2005Inventors: Sylvain Cardinaud, Andre Habel, Pierre Langlade-Demoyen, Francois Lemonnier